Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Cordyceps TCM-700C is a botanical drug preparation developed as a hepatoprotective agent. It is formulated from traditional Chinese medicinal ingredients, with cordyceps as a key component. Preclinical studies have demonstrated that TCM-700C exhibits potent protective effects against chemically induced liver damage in animal models, outperforming silymarin in several biochemical and histological parameters. The mechanism of action appears to involve antioxidant activity—restoring levels of glutathione and catalase—and reducing liver fibrosis. The product has been approved for phase II clinical trials by both the U.S. FDA and Taiwan's Department of Health and has received patents in Taiwan and China[1][2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Cordyceps TCM-700C.